{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:46:45Z","timestamp":1784958405241,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T00:00:00Z","timestamp":1391040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10875-014-9990-x","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T05:39:39Z","timestamp":1390973979000},"page":"190-196","source":"Crossref","is-referenced-by-count":21,"title":["Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes"],"prefix":"10.1007","volume":"37","author":[{"given":"Ralph S.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Bonagura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,30]]},"reference":[{"issue":"5 Suppl 1","key":"9990_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)61142-8","volume":"94","author":"FA Bonilla","year":"2005","unstructured":"Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and treatment of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1\u2013S63.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"9990_CR2","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.jaci.2010.02.040","volume":"125","author":"M Lucas","year":"2010","unstructured":"Lucas M, Lee M, Lortan J, Lopez-Granadas E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354\u201360.","journal-title":"J Allergy Clin Immunol"},{"key":"9990_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21\u201330.","journal-title":"Clin Immunol"},{"issue":"2","key":"9990_CR4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","volume":"169","author":"JS Orange","year":"2012","unstructured":"Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012;169(2):172\u201381.","journal-title":"Clin Exp Immunol"},{"key":"9990_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","volume":"122","author":"VR Bonagura","year":"2008","unstructured":"Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008;122:210\u20131.","journal-title":"J Allergy Clin Immunol"},{"key":"9990_CR6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11882-002-0069-z","volume":"2","author":"M Berger","year":"2002","unstructured":"Berger M. A history of immune globulin therapy, from the Harvard Crash Program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368\u201378.","journal-title":"Curr Allergy Asthma Rep."},{"key":"9990_CR7","unstructured":"FDA. Summary basis for approval: immune globulin intravenous (human), 10% solution (Gammagard Liquid). 2004. Available at: http:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/bloodbloodproducts\/approvedproducts\/licensedproductsblas\/fractionatedplasmaproducts\/ucm224271.pdf . Accessed 17 Oct 2013."},{"issue":"3","key":"9990_CR8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10875-011-9511-0","volume":"31","author":"I Quinti","year":"2011","unstructured":"Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315\u201322.","journal-title":"J Clin Immunol"},{"key":"9990_CR9","unstructured":"Wasserman RL, Zidik J. Clinical utility of biweekly dosing with high concentration subcutaneous immunoglobulin in patients with primary immunodeficiency: retrospective case series. Presented at the Annual Meeting of the American College of Asthma, Allergy and Immunology; Nov. 7\u201311, 2013; Baltimore, MD."},{"key":"9990_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1057\/rm.2009.17","volume":"6","author":"S Skoda-Smith","year":"2010","unstructured":"Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1\u201310.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"9990_CR11","first-page":"26","volume":"21","author":"EA Goddard","year":"2008","unstructured":"Goddard EA. Intravenous immunoglobulin. Curr Allergy Clin Immunol. 2008;21(1):26\u201331.","journal-title":"Curr Allergy Clin Immunol"},{"key":"9990_CR12","unstructured":"Immune Deficiency Foundation Patient Survey. Treatment experiences and preferences among patients with primary immunodeficiency diseases national survey of patients. 2008. Immune Deficiency Foundation. Available at: http:\/\/primaryimmune.org\/idf-survey-research-center\/idf-surveys . Accessed 17 Oct 2013."},{"key":"9990_CR13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0091-6749(91)90301-4","volume":"88","author":"RI Schiff","year":"1991","unstructured":"Schiff RI, Sedlak D, Buckley RH. Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. J Allergy Clin Immunol. 1991;88:61\u20137.","journal-title":"J Allergy Clin Immunol"},{"key":"9990_CR14","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/WNL.57.9.1699","volume":"57","author":"JA Grillo","year":"2001","unstructured":"Grillo JA, Gorson KC, Ropper AH, Lewis J, Weinstein R. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders. Neurology. 2001;57:1699\u2013701.","journal-title":"Neurology"},{"issue":"4","key":"9990_CR15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10875-012-9656-5","volume":"32","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, et al. Safety, efficacy and pharmacokinetics of a new 10\u00a0% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol. 2012;32(4):663\u20139.","journal-title":"J Clin Immunol"},{"issue":"2","key":"9990_CR16","first-page":"139","volume":"19","author":"S Dashti-Khavidaki","year":"2009","unstructured":"Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, Movahedi M, Parvaneh N, Pouladi N, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol. 2009;19(2):139\u201345.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"Suppl 1","key":"9990_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2249.2009.04023.x","volume":"158","author":"M Ballow","year":"2009","unstructured":"Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, et al. Immunodeficiencies. Clin Exp Immunol. 2009;158 Suppl 1:14\u201322.","journal-title":"Clin Exp Immunol"},{"key":"9990_CR18","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease. A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"9990_CR19","first-page":"4","volume":"28 Spec No.1","author":"F Fakhouri","year":"2007","unstructured":"Fakhouri F. Intravenous immunoglobulins and acute renal failure: mechanism and prevention. Rev Med Interne. 2007;28 Spec No.1:4\u20136.","journal-title":"Rev Med Interne"},{"issue":"5","key":"9990_CR20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.mbc.0000172694.85233.a8","volume":"16","author":"D Paran","year":"2005","unstructured":"Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313\u20138.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"9990_CR21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1546-0096-9-28","volume":"9","author":"Y Kemmotsu","year":"2011","unstructured":"Kemmotsu Y, Nakayama T, Matsuura H, Saji T. Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease. Pediatr Rheumatol Online J. 2011;9:28.","journal-title":"Pediatr Rheumatol Online J."},{"issue":"3","key":"9990_CR22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","volume":"29","author":"H Ohrbach","year":"2005","unstructured":"Ohrbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29(3):173\u201384.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"9990_CR23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1345\/aph.1E040","volume":"38","author":"SA Chapman","year":"2004","unstructured":"Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38(12):2059\u201367.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"9990_CR24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.2215\/CJN.01701105","volume":"1","author":"AA Vo","year":"2006","unstructured":"Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol. 2006;1(4):844\u201352.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"9990_CR25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1002\/lt.20594","volume":"11","author":"P Boros","year":"2005","unstructured":"Boros P, Gondolesi G, Bromberg JS. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl. 2005;11(12):1469\u201380.","journal-title":"Liver Transpl"},{"key":"9990_CR26","unstructured":"Hasan A. Reducing adverse reactions in home IVIG administration. Infusion. 2012. Available at: http:\/\/onlinedigeditions.com\/display_article.php?id=1018713 . Accessed 17 Oct 2013."},{"key":"9990_CR27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2249.2010.04195.x","volume":"161","author":"RL Wasserman","year":"2010","unstructured":"Wasserman RL, Irani AM, Tracy J, Tsoukas C, Stark D, Levy R, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10\u00a0% caprylate\/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518\u201326.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"9990_CR28","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1651-2227.2007.00485.x","volume":"96","author":"A Fasth","year":"2007","unstructured":"Fasth A, Nystr\u00f6m J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96(10):1474\u20138.","journal-title":"Acta Paediatr"},{"issue":"12","key":"9990_CR29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/j.1552-4604.1991.tb03688.x","volume":"31","author":"KH Rand","year":"1991","unstructured":"Rand KH, Gibbs K, Derendorf H, Graham-Pole J. Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol. 1991;31(12):1151\u20134.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"9990_CR30","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s10875-011-9588-5","volume":"31","author":"M Borte","year":"2011","unstructured":"Borte M, Quinti I, Soresina A, Fern\u00e1ndez-Cruz E, Ritchie B, Schmidt DS, et al. Efficacy and safety of subcutaneous Vivaglobin\u00ae replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011;31(6):952\u201361.","journal-title":"J Clin Immunol"},{"key":"9990_CR31","unstructured":"GAMMAGARD LIQUID (Immune Globulin Intravenous [Human]), 10\u00a0% solution, for intravenous and subcutaneous administration. Prescribing information. Westlake Village, CA: Baxter Healthcare Corporation; 2012."},{"key":"9990_CR32","unstructured":"Vivaglobin (Immune Globulin Subcutaneous [Human]), 16\u00a0% liquid. Prescribing information. King of Prussia, PA: CSL Behring LLC; Rev. April 2010."},{"key":"9990_CR33","unstructured":"Hizentra (Immune Globulin Subcutaneous [Human]), 20\u00a0% liquid. Prescribing information. King of Prussia, PA: CSL Behring LLC; Rev. Oct. 2011."},{"key":"9990_CR34","first-page":"277","volume":"6","author":"L Kobrynski","year":"2012","unstructured":"Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics. 2012;6:277\u201387.","journal-title":"Biologics"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-014-9990-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-014-9990-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-014-9990-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-014-9990-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T04:14:59Z","timestamp":1559276099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-014-9990-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,30]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["9990"],"URL":"https:\/\/doi.org\/10.1007\/s10875-014-9990-x","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,30]]}}}